Effect of AI-Supported Virtual Patient Chatbot Training on Nursing Students' Self-Perceived Clinical Decision-Making and Gynecological Cancer Knowledge
Effect of AI-Supported Virtual Patient Chatbot Training on Nursing Students' Self-Perceived Clinical Decision-Making and Gynecological Cancer Knowledge: A Randomized Controlled Trial
This randomized controlled trial evaluated the effects of structured case-based training delivered through an artificial intelligence-supported educational virtual patient chatbot platform on nursing students' gynecological cancer knowledge and self-perceived clinical decision-making. Third-year undergraduate nursing students who had completed the Obstetrics and Gynecology Nursing course were randomly assigned in a 1:1 ratio to an intervention group or an assessment-only wait-list control group. The intervention group completed five AI-supported virtual patient training scenarios during a two-week access period, followed by a common virtual patient assessment. The control group completed the same virtual patient assessment without access to the training scenarios during the study assessment period. Knowledge and self-perceived clinical decision-making were assessed at baseline and immediately after the assigned study procedures. Virtual patient performance was assessed once at the final assessment.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Turkey
-
Sakarya, Turkey, Turkey (Türkiye), 54050
- Sakarya University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Enrolled as a third-year undergraduate nursing student.
- Successfully completed the Obstetrics and Gynecology Nursing (Women's Health and Diseases Nursing) course.
- Volunteered to participate and provided digital informed consent.
Exclusion Criteria:
- No additional exclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AI-Supported Virtual Patient Chatbot Training Group
Participants received access to five sequential AI-supported educational virtual patient scenarios addressing cervical, endometrial, ovarian, vulvar, and vaginal cancers. The scenarios were completed during a two-week access period. Participants responded in free text, received immediate individualized formative feedback, and were allowed up to three response attempts per scenario. After completing all five training scenarios, participants completed the common virtual patient assessment and the immediate post-intervention outcome assessments. |
A web-based educational platform integrating structured gynecological oncology scenarios, AI-supported virtual patient interaction, predefined performance criteria, sequential progression, and immediate individualized formative feedback. Participants completed five training scenarios during a two-week access period. The platform used the Claude Sonnet 4 model, API identifier claude-sonnet-4-20250514, throughout the study. |
|
No Intervention: Assessment-Only Wait-List Control Group
Participants did not receive access to the AI-supported training scenarios during the outcome assessment period. They completed the baseline assessments, the same common virtual patient assessment as the intervention group, and the immediate post-assessment knowledge and clinical decision-making measures. After completing all study outcome assessments, they were granted access to the AI-supported educational scenarios. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Clinical Decision Making in Nursing Scale-Turkish Version (CDMNS-Tr) Score
Time Frame: Baseline, before access to any group-specific study procedure, and immediately after completion of the assigned study procedures.
|
The CDMNS-Tr is a 40-item scale assessing self-reported clinical decision-making. Items are rated on a 5-point Likert scale ranging from 1 (never) to 5 (always), with eighteen negatively worded items being reverse-scored. Total scores range from 40 to 200, with higher scores indicating a higher self-perception of clinical decision-making abilities. |
Baseline, before access to any group-specific study procedure, and immediately after completion of the assigned study procedures.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Gynecological Oncology Knowledge Test Total Score
Time Frame: Baseline, before access to any group-specific study procedure, and immediately after completion of the assigned study procedures, within approximately two weeks after baseline.
|
The researcher-developed test consists of 15 multiple-choice items assessing the pathophysiology, clinical manifestations, diagnosis, treatment, complications, and nursing care of gynecological cancers. Correct answers are scored as 1 and incorrect or unanswered items as 0. Total scores range from 0 to 15, with higher scores indicating greater knowledge. Change was evaluated by comparing baseline and immediate post-intervention total scores. |
Baseline, before access to any group-specific study procedure, and immediately after completion of the assigned study procedures, within approximately two weeks after baseline.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 02.09.2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.